Serum S-100beta as a possible marker of blood-brain barrier disruption.
Two brain-specific proteins, S-100beta and neuron-specific enolase (NSE), are released systemically after cerebral lesions, but S-100beta levels sometimes rise in the absence of neuronal damage. We hypothesized that S-100beta is a marker of blood-brain barrier (BBB) leakage rather than of neuronal damage. We measured both proteins in the plasma of patients undergoing iatrogenic BBB disruption with mannitol, followed by chemotherapy. Serum S-100beta increased significantly after mannitol infusion (P<0.05) while NSE did not. This suggests that S-100beta is an early marker of BBB opening that is not necessarily related to neuronal damage.
Kapural
M
M
Department of Neurological Surgery, Cleveland Clinic Foundation NB-20, 9500 Euclid Avenue, NB2-137, Cleveland, OH 44195, USA.
Krizanac-Bengez
Lj
Lj
Barnett
G
G
Perl
J
J
Masaryk
T
T
Apollo
D
D
Rasmussen
P
P
Mayberg
M R
MR
Janigro
D
D
D015415:Biomarkers / Q000097:blood; D001812:Blood-Brain Barrier / Q000187:drug effects*; D016543:Central Nervous System Neoplasms / Q000097:blood* / Q000188:drug therapy; D004334:Drug Administration Schedule; D006801:Humans; D007261:Infusions, Intra-Arterial; D008223:Lymphoma / Q000097:blood* / Q000188:drug therapy; D008353:Mannitol / Q000008:administration & dosage*; D009414:Nerve Growth Factors; D010751:Phosphopyruvate Hydratase / Q000097:blood; D011237:Predictive Value of Tests; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood*
D015415:Biomarkers; D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; D008353:Mannitol; D010751:Phosphopyruvate Hydratase